111 related articles for article (PubMed ID: 31425728)
1. Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development.
Baldrick P; Hutchings JW; Heath MD; Skinner MA
Regul Toxicol Pharmacol; 2019 Nov; 108():104441. PubMed ID: 31425728
[TBL] [Abstract][Full Text] [Related]
2. New toxicity testing of PQ grass allergy immunotherapy to support product development.
Baldrick P; Hutchings JW; Heath MD; Skinner MA; Martin T; Gray C
J Appl Toxicol; 2019 Oct; 39(10):1462-1469. PubMed ID: 31231859
[TBL] [Abstract][Full Text] [Related]
3. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy.
Baldrick P; Richardson D; Woroniecki SR; Lees B
J Appl Toxicol; 2007; 27(4):399-409. PubMed ID: 17299813
[TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant.
Baldrick P; Richardson D; Elliott G; Wheeler AW
Regul Toxicol Pharmacol; 2002 Jun; 35(3):398-413. PubMed ID: 12202055
[TBL] [Abstract][Full Text] [Related]
5. Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy.
Baldrick P; Richardson D; Wheeler AW; Woroniecki SR
J Appl Toxicol; 2004; 24(4):261-8. PubMed ID: 15300713
[TBL] [Abstract][Full Text] [Related]
6. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy.
Baldrick P; Richardson D; Wheeler AW
Vaccine; 2001 Dec; 20(5-6):737-43. PubMed ID: 11738737
[TBL] [Abstract][Full Text] [Related]
7. The Impact on Allergy-Related Cells of a Birch Pollen Allergoid, with and without Monophosphoryl Lipid A, in Comparison with the Native Equivalent.
Worm M; Ernst D; Kraller M; Babina M
Int Arch Allergy Immunol; 2017; 172(1):20-26. PubMed ID: 28219062
[TBL] [Abstract][Full Text] [Related]
8. Reproduction and juvenile animal toxicology studies in the rat with a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL(®)) for the treatment of grass pollen allergy.
Baldrick P; Hewings S; Skinner M
Reprod Toxicol; 2011 Nov; 32(3):322-8. PubMed ID: 21782016
[TBL] [Abstract][Full Text] [Related]
9. A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy.
Reeve L; Baldrick P; Hewings S; Skinner M
J Appl Toxicol; 2012 Aug; 32(8):608-16. PubMed ID: 21919021
[TBL] [Abstract][Full Text] [Related]
10. Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL).
Hopkins M; Lees BG; Richardson DG; Woroniecki SR; Wheeler AW
Allergol Immunopathol (Madr); 2001; 29(6):245-54. PubMed ID: 11834183
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
[TBL] [Abstract][Full Text] [Related]
12. Chinese Birch Pollen Allergy and Immunotherapy in Mice.
Xie Z; Yin J
Inflammation; 2019 Jun; 42(3):961-972. PubMed ID: 30715691
[TBL] [Abstract][Full Text] [Related]
13. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
Larenas-Linnemann D
Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
[TBL] [Abstract][Full Text] [Related]
15. Safety evaluation of standardized allergen extract of Japanese cedar pollen for sublingual immunotherapy.
Mitobe Y; Yokomoto Y; Ohashi-Doi K
Regul Toxicol Pharmacol; 2015 Apr; 71(3):529-40. PubMed ID: 25701184
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents.
Drachenberg KJ; Heinzkill M; Urban E; Woroniecki SR
Allergol Immunopathol (Madr); 2003; 31(5):270-7. PubMed ID: 14572416
[TBL] [Abstract][Full Text] [Related]
17. Allergen immunotherapy for birch pollen-allergic patients: recent advances.
Moingeon P; Floch VB; Airouche S; Baron-Bodo V; Nony E; Mascarell L
Immunotherapy; 2016 May; 8(5):555-67. PubMed ID: 27140409
[TBL] [Abstract][Full Text] [Related]
18. Allergen immunotherapy for birch-apple syndrome: what do we know?
Incorvaia C; Ridolo E; Mauro M; Russello M; Pastorello E
Immunotherapy; 2017 Nov; 9(15):1271-1278. PubMed ID: 29130794
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy.
Zielen S; Gabrielpillai J; Herrmann E; Schulze J; Schubert R; Rosewich M
Immunotherapy; 2018 Jun; 10(7):529-536. PubMed ID: 29562801
[TBL] [Abstract][Full Text] [Related]
20. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
Buczyłko K; van der Werf JF; Boot D; van Ree R
Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
